All three FDA-approved PARP inhibitors (Olaparib, Niraparib, and Rucaparib) show potential synergy with crizotinib by preventing DNA repair in cancer cells already stressed by crizotinib-induced damage. This evidence concerns the gene PARP1 and cancer.